Jonathon P. Orme

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase

Richard A. Norman, Anne-Kathrin Schott, David Andrews et al. · Journal of Medicinal Chemistry · 2012 · 46 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro

Michael Gwilt, C G Henderson, Jonathon P. Orme et al. · European Journal of Pharmacology · 1992 · 36 citations

Medicine, Cardiology, Pharmacology +13